MX2023011619A - Nuevos anticuerpos anti-sema3a y usos de los mismos. - Google Patents
Nuevos anticuerpos anti-sema3a y usos de los mismos.Info
- Publication number
- MX2023011619A MX2023011619A MX2023011619A MX2023011619A MX2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A
- Authority
- MX
- Mexico
- Prior art keywords
- sema3a
- seq
- sequence
- binds
- activity
- Prior art date
Links
- 102000013008 Semaphorin-3A Human genes 0.000 abstract 9
- 108010090319 Semaphorin-3A Proteins 0.000 abstract 9
- 230000027455 binding Effects 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 2
- 238000010494 dissociation reaction Methods 0.000 abstract 2
- 230000005593 dissociations Effects 0.000 abstract 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 abstract 2
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 210000000020 growth cone Anatomy 0.000 abstract 1
- 210000003584 mesangial cell Anatomy 0.000 abstract 1
- 238000010232 migration assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un anticuerpo aislado o su fragmento de unión a antígeno que se une con Sema3A humana. El anticuerpo aislado o fragmento de unión a antígeno de acuerdo con la presente invención i) se une con Sema3A humana de la secuencia de SEQ ID NO: 600 con una constante de disociación (KD) = 50 nM, = 20 nM, = 10 nM, = 1 nM o = 0,1 nM; ii) reacciona en forma cruzada con Sema3A de ratón, cinomolgus, rata, cerdo y/o perro, en particular en donde dicho anticuerpo aislado o su fragmento de unión a antígeno se une con Sema3A de ratón, cinomolgus, rata, cerdo y/o perro con una constante de disociación (KD) = 50 nM, = 20 nM, = 10 nM, = 1 nM o = 0,1 nM; iii) se une con Sema3A humana de la secuencia de SEQ ID NO: 600 con una actividad de unión medida por resonancia de plasmón superficial (SPR) de = 60%, = 70%, = 80% o = 90%; iv) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de migración de células mesangiales in vitro con una EC50 de = 10 nM, = 5 nM, = 2,5 nM o = 1 nM; v) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de colapso de cono de crecimiento in vitro con una EC50 de = 50 nM, = 25 nM, = 10 nM o = 5 nM; vi) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de repulsión HUVEC in vitro con una EC50 de = 1 nM o = 0,3 nM, = 0,1 nM, = 0,07 nM, = 0,06 nM y/o vii) exhibe una mayor potencia contra Sema3A celular, de la secuencia de SEQ ID NO: 600, repulsión inducida por HUVEC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21165960 | 2021-03-30 | ||
PCT/EP2022/058123 WO2022207554A1 (en) | 2021-03-30 | 2022-03-28 | Anti-sema3a antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023011619A true MX2023011619A (es) | 2023-10-11 |
Family
ID=75302351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023011619A MX2023011619A (es) | 2021-03-30 | 2022-03-28 | Nuevos anticuerpos anti-sema3a y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220389096A1 (es) |
EP (1) | EP4314047A1 (es) |
JP (1) | JP2024512633A (es) |
KR (1) | KR20230162800A (es) |
CN (1) | CN117396504A (es) |
AR (1) | AR125240A1 (es) |
AU (1) | AU2022251786A1 (es) |
BR (1) | BR112023018061A2 (es) |
CA (1) | CA3215274A1 (es) |
IL (1) | IL307233A (es) |
MX (1) | MX2023011619A (es) |
PE (1) | PE20240357A1 (es) |
TW (1) | TW202304975A (es) |
WO (1) | WO2022207554A1 (es) |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
WO2008112640A2 (en) | 2007-03-09 | 2008-09-18 | Sinomab Bioscience Limited | Construction and use of a functionally human antibody library with maximized repertoire diversity |
DK2955195T3 (da) * | 2013-02-06 | 2019-05-06 | Univ Yokohama City | Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme |
WO2017074013A1 (ko) | 2015-10-27 | 2017-05-04 | 사회복지법인 삼성생명공익재단 | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 |
CR20210559A (es) * | 2019-05-09 | 2021-12-23 | Boehringer Ingelheim Int | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
WO2020261281A1 (en) * | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
-
2022
- 2022-03-28 BR BR112023018061A patent/BR112023018061A2/pt unknown
- 2022-03-28 CN CN202280038261.5A patent/CN117396504A/zh active Pending
- 2022-03-28 JP JP2023560024A patent/JP2024512633A/ja active Pending
- 2022-03-28 PE PE2023002753A patent/PE20240357A1/es unknown
- 2022-03-28 US US17/706,543 patent/US20220389096A1/en active Pending
- 2022-03-28 KR KR1020237036770A patent/KR20230162800A/ko unknown
- 2022-03-28 WO PCT/EP2022/058123 patent/WO2022207554A1/en active Application Filing
- 2022-03-28 CA CA3215274A patent/CA3215274A1/en active Pending
- 2022-03-28 EP EP22713427.7A patent/EP4314047A1/en active Pending
- 2022-03-28 AU AU2022251786A patent/AU2022251786A1/en active Pending
- 2022-03-28 IL IL307233A patent/IL307233A/en unknown
- 2022-03-28 MX MX2023011619A patent/MX2023011619A/es unknown
- 2022-03-29 AR ARP220100753A patent/AR125240A1/es unknown
- 2022-03-30 TW TW111112217A patent/TW202304975A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112023018061A2 (pt) | 2023-10-03 |
EP4314047A1 (en) | 2024-02-07 |
TW202304975A (zh) | 2023-02-01 |
US20220389096A1 (en) | 2022-12-08 |
IL307233A (en) | 2023-11-01 |
CA3215274A1 (en) | 2022-10-06 |
PE20240357A1 (es) | 2024-02-27 |
AR125240A1 (es) | 2023-06-28 |
JP2024512633A (ja) | 2024-03-19 |
AU2022251786A1 (en) | 2023-10-05 |
WO2022207554A1 (en) | 2022-10-06 |
KR20230162800A (ko) | 2023-11-28 |
CN117396504A (zh) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009111884A (ru) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования | |
CN111108119B (zh) | 新型抗CD3ε抗体 | |
RU2005132389A (ru) | Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами | |
RS52592B (en) | ANTI-HEPCIDINE ANTIBODIES AND THEIR USE | |
HRP20150162T1 (hr) | Antikin antitijela koja se vežu na višestruke cc kemokine | |
JP2016135783A5 (es) | ||
RS52804B (en) | HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE | |
RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
AU2013310924B2 (en) | Method for producing antibody molecules having inter-species, intra-target cross-reactivity | |
RS53595B1 (en) | ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE | |
RU2013138469A (ru) | АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ | |
WO2007111714B1 (en) | Il-21 antagonists | |
CN1997893A (zh) | 抗体测定法 | |
CO6231000A2 (es) | Anticuerpos contra de erbb3 y usos de los mismos | |
JP2021501744A5 (es) | ||
NZ584838A (en) | Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof | |
RS54066B1 (en) | COMPLETELY HUMAN ANTI-VAP-1 MONOCLONAL ANTIBODIES | |
RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
AU6943800A (en) | Antibodies specific for fullerenes | |
CN112111011B (zh) | 一种特异性抗噻虫嗪抗体的可变区序列及其重组全长抗体 | |
MX2023011619A (es) | Nuevos anticuerpos anti-sema3a y usos de los mismos. | |
DE69937369D1 (de) | CCR5 Antikörper PA14 | |
RU2010152690A (ru) | Белки, связывающие рецептор интерлейкина-21 | |
US11884743B2 (en) | Preparation and application of an intact recombinant antibody specific to clothianidin based on the identified variable region sequence | |
CN108456252B (zh) | 高特异性的抗兔IgG天然构象单克隆抗体 |